Allscripts to Participate in National Precision Medicine Initiative
“By inviting patients to contribute their data to ground-breaking research efforts such as the PMI Cohort Program, this collaborative industry effort will speed progress in delivering the benefits of a precision medicine approach to healthcare professionals and patients alike,” Allscripts Chief Executive Officer
In addition to this initiative, Allscripts has demonstrated its commitment to precision medicine in several ways:
- Formed and funded in 2015, the Allscripts Precision Medicine business unit is mapping out the semantic integration of genomic research, personalized data and clinical information held within electronic health records (EHRs). The ultimate goal is to help clinicians make informed decisions by integrating complex data sets and delivering actionable insights at the point of care.
- Allscripts and NantHealth, a cloud-based information technology company founded by Dr.
Patrick Soon-Shiong, MD, formed a strategic alliance in March of 2015. Together, the companies intend to develop an integrated, evidence-based personalized approach to healthcare solutions, starting with cancer care.
- Under Vice President
Joe Biden’sleadership, the National Cancer Moonshot is a coalition working to help cancer fighters share information and accelerate research efforts. Allscripts helped inform the conversation with the Vice President and joins several organizations, including Allscripts Sunrise™ client National Institutes of Health(NIH), to speed the advance of cancer research over the next five years.
- Through the
National Immunotherapy Coalition, Allscripts joins leaders from biotech and pharmaceutical companies, academic cancer centers and providers to validate the potential of combination immunotherapy as the next standard of care for cancer patients. The coalition aims to complete randomized Phase II trials in patients at all stages of disease in up to 20 tumor types in 20,000 patients within the next two years.
“The United States healthcare system does not deliver the best possible outcomes to patients, and a lot of unnecessary money is spent because of a one-size-fits-all approach to treating patients,” Senior Vice President and General Manager for Allscripts Precision Medicine Assaf Halevy, said. “The reality is that we can be more precise today with the knowledge we have. We believe that enabling genomic-based interventions at the point of care and in the clinician’s workflow will make treatment more precise.”
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of
For more information contact: Investors:
Seth Frank312-506-1213 firstname.lastname@example.org Media: Concetta DiFranco312-447-2466 email@example.com